Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061244 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL7588597 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL5356889 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL8906942 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL3207889 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL23727498 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL3650896 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL8906883 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL662237 | 0.98 | DUT (0.36) | DUT | |
| SCHEMBL1578618 | 0.94 | DUT (0.37) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| US-12077555-B2 | STAT degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230120381-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230084113-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11485750-B1 | STAT degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| EP-3946360-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020206424-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2009111830-A1 | CONJUGATED UNSATURATED COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2009-09-17 | — | — | WO | disclosed |
| US-7074819-B2 | Benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-07-11 | — | — | US | disclosed |
| WO-2001042236-A1 | METAL SALTS OF 3-METHYL-CHROMANE OR THIOCHROMANE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-06-14 | — | — | WO | disclosed |
| EP-1087959-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-04-04 | — | — | EP | disclosed |
| US-6153768-A | RECEPTOR BLOCKING ANTIESTROGENS HAVING REDUCED SIDE EFFECTS | C & C RESEARCH LABORATORIES (KR) | 2000-11-28 | — | — | US | disclosed |
| WO-1999065893-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1999-12-23 | — | — | WO | disclosed |
| EP-0944613-A1 | NOVEL BENZOPYRAN DERIVATIVES | C & C Research Laboratories (KR) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025916-A1 | NOVEL BENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1998-06-18 | — | — | WO | disclosed |
| US-4983627-A | Treating atherosclerosis, thrombosis and vasospasms; anticholesterol,-secretory,-ulcer and hypotensive agents | SYNTEX (U.S.A.) INC. (US) | 1991-01-08 | — | — | US | disclosed |
| EP-0163416-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-31 | — | — | EP | disclosed |
| US-4751240-A | ANTIFERTILITY AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-06-14 | — | — | US | disclosed |
| EP-0163416-A2 | Phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230084113-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | DUT 1123/4885CYP1A2 486/4885CYP2D6 698/4885 |
| US-20230120381-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | DUT 1123/4885CYP1A2 486/4885CYP2D6 698/4885 |
| US-12077555-B2 | STAT degraders and uses thereof | STAT4, STAT1, STAT3 | DUT 1123/4885CYP1A2 486/4885CYP2D6 698/4885 |
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | DUT 1123/4885CYP1A2 486/4885CYP2D6 698/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | DUT 1123/4885CYP1A2 486/4885CYP2D6 698/4885 |
| US-11485750-B1 | STAT degraders and uses thereof | STAT4, STAT1, STAT3 | DUT 1123/4885CYP1A2 486/4885CYP2D6 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.